Mycobacterium tuberculosis and sulfamethoxazole susceptibility.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.Journal of the International AIDS Society · 2019
   Observational
2. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.The Journal of antimicrobial chemotherapy · 2017
   Article
3. Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.Nature microbiology · 2017
   Article
4. Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of Tuberculosis.Antimicrobial agents and chemotherapy · 2016
   Article
5. Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.Antimicrobial agents and chemotherapy · 2015
   Article
6. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2014
   Article
7. Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.PloS one · 2014
   Article
8. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.Antimicrobial agents and chemotherapy · 2014
   Article
9. In vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in France.Antimicrobial agents and chemotherapy · 2013
   Article
10. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.The Journal of biological chemistry · 2013
    Article
11. Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistance.Antimicrobial agents and chemotherapy · 2012
    Review
12. The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2012
    Article
13. Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.Expert review of anti-infective therapy · 2012
    Article
14. Strategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosis.Expert review of anti-infective therapy · 2012
    Review
15. Bacterial conversion of folinic acid is required for antifolate resistance.The Journal of biological chemistry · 2011
    Article
16. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.Antimicrobial agents and chemotherapy · 2010
    Article

Corrections and comments

• Comment on
  Tuberculosis and trimethoprim-sulfamethoxazole.2009

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as